Novel Gellan Gum-Based In Situ Nanovesicle Formulation of Docetaxel for Its Localized Delivery Using Depot Formation

In the present study, different in situ hydrogel formulations of docetaxel (DTX) based on biocompatible polymers such as Hyaluronic Acid (HA), poloxamer-407, chitosan and gellan gum were formulated to increase its therapeutic efficacy reduce toxicity. DTX was loaded nanovesicles (20 mg/mL equivalent commercial strength) further incorporated into bases possess a dual rationale protection against burst release enhanced solubility drug. The optimized formulation (NV-TPGS-3-GG-4) showed ideal rheological behavior characteristics at 37±0.5°C with sustained more than 144 h. had instant vitro gelation (2.8±0.3 min) good injectability comparison conventional injectable having (<2 h). Additionally, developed exhibited an improved biodisponibility (25.1±0.2 h) commercially available (1.7±0.1 Solid Tumor Carcinoma model Swiss albino mice revealed that (based gum) better tumor reduction (85.7±1.2%) lower toxicity compared (77.3±1.3%). Pharmacokinetic biodistribution studies demonstrated 3 4 times higher localization drug tumors. Our findings suggested gum-based can be effective delivery system for solubility, reduced toxicity, targeting tumors therapeutics. Graphical abstract